OSU-HDAC42 is an orally available, broad spectrum histone-deacetylase inhibitor that possesses additional mechanisms as well. In preclinical studies OSU-HDAC42 has demonstrated greater potency and a competitive profile in solid and liquid tumors when compared with vorinostat (SAHA), the leading marketed compound in the class. Arno plans to initiate Phase I studies of OSU-HDAC42 in liquid and solid tumors in 2009.




Publications

• Chen CS, Wang YC, Yang HC, Huang PH et al., Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Research, 67:5318-27, 2007.
• Lu YS, Kashida Y, Kulp SK, Wang YC et al., Efficacy of ISU-HDAC42, a Novel Histone Deacetylase Inhibitor, in Murine Models of Hepatocellular Carcinoma. Hpatology, Vol. 46, No. X, 2007.
• Kulp SK, Chen CS, Wang D, Chen CY and Chen CS. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clinical Cancer Research 12:5199-206, 2006.
• Chen CS, Weng SC, Tseng PH, Lin HP, and Chen CS. Nonepigenetic effects of histone deacetylase inhibitors on Akt through reshuffling protein phosphatae-1 complexes. J Biol Chem, 280:38879-38887, 2005.
• Chen CS, Weng SC, Tseng PH, Lin HP, and Chen CS, Histone Acetylation-independent Effect on Histone Deacetylase Inhibitors on Akt through the Reshuffling of Protein Phosphatase 1 Complexes. Journal of Biological Chemistry November 18, 2005: Volume 280: Number 46.